Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide

Diabetes Research and Clinical Practice
Savvoula SavvidouJohn Goulis

Abstract

Diabetes mellitus type 2 (DMT2) and non-alcoholic fatty liver disease (NAFLD) are both characterized by decreased circulating adiponectin. Recently, glucagon-like peptide-1 receptor agonists have been shown to induce adiponectin's expression. However, their interaction on clinical grounds needs to be further elucidated. DMT2 patients with abnormal aminotransferases were screened for NAFLD and subjected to liver biopsy (group A, n=17). A subgroup of patients (n=110), after assessed for eligibility criteria, was blindly randomized to receive either 6-month exenatide supplementation on glargine insulin (group B) or intense, self-regulated, insulin therapy alone (group C). Baseline patient characteristics: 49(38.6%) males, aged 63.1 ± 7.5 years-old, BMI 32.9 ± 4.9 kg/m(2), HbA1c 8.1 ± 1.2% (65 ± 14 mmol/mol), median ALT 23 U/L (range 5-126), AST 20 U/L (7-72). Group A had biopsy-proven NAFLD with a median Activity Score of 5 and fibrosis stage 3. Presence of NAFLD was accompanied by a significant decline in adiponectin (p<0.001), which was negatively correlated with the degree of ALT in all groups (Spearman's correlation, rs=-0.644, p<0.001). In the subgroup intervention trial, adiponectin was significantly raised in both groups B ...Continue Reading

References

May 30, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Pouneh MofradArun J Sanyal
Nov 25, 2004·Best Practice & Research. Clinical Gastroenterology·Helena Cortez-Pinto, Maria Ermelinda Camilo
May 26, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David E KleinerUNKNOWN Nonalcoholic Steatohepatitis Clinical Research Network
Dec 24, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiaokun DingFrank A Anania
Sep 7, 2006·Liver International : Official Journal of the International Association for the Study of the Liver·Maarten E TushuizenRobert J Heine
Sep 16, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Melania Manco, Gianfranco Bottazzo
Mar 1, 2008·Journal of Diabetes Science and Technology·Loretta L NielsenByron Hoogwerf
Mar 13, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nitika Arora GuptaFrank A Anania
Mar 25, 2010·BMJ : British Medical Journal·Kenneth F SchulzUNKNOWN CONSORT Group
Jul 13, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Gianluca Svegliati-BaroniAmalia Gastaldelli
Sep 13, 2011·Expert Opinion on Emerging Drugs·Asger LundTina Vilsbøll
Sep 16, 2011·Clinical and Experimental Pharmacology & Physiology·Hui SuXin-Liang Ma
Oct 13, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·N Sattar
Nov 19, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Jens Pedersen, Jens Juul Holst
May 1, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·G DerosaP Maffioli
Sep 22, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David van der PoortenJacob George
Feb 26, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Lili ZhangGangyi Yang
Jan 10, 2014·Arquivos brasileiros de endocrinologia e metabologia·Hui FanXinChun Yang
Jan 15, 2014·Best Practice & Research. Clinical Endocrinology & Metabolism·Kenneth K Y ChengAimin Xu
Mar 19, 2014·Diabetes Research and Clinical Practice·L GuariguataJ E Shaw

❮ Previous
Next ❯

Citations

Jul 6, 2016·Pharmacogenomics·Gregor LorbekDamjana Rozman
Apr 22, 2019·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kenneth Cusi
Sep 22, 2020·World Journal of Hepatology·Areti SofogianniEvangelos Cholongitas
Jan 20, 2021·Diabetes, Obesity & Metabolism·Bertrand CariouArun J Sanyal
Apr 10, 2021·British Journal of Clinical Pharmacology·Luis E Simental-MendíaMario Simental-Mendía
Dec 15, 2020·Clinics and Research in Hepatology and Gastroenterology·Maria-Styliani KalogirouEmmanouil Sinakos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.